Originally FDA-approved for type 2 diabetes, several now carry indications for weight management and cardiovascular risk reduction
These specialists assess your entire metabolic profile, including thyroid function, insulin resistance, cortisol levels, and other hormonal factors that might influence weight management
En relacin a los efectos adversos de estos frmacos, generalmente son bien tolerados y transitorios, por lo que no constituyen una razn para su discontinuacin
Additional considerations include: Gastrointestinal effects : Wegovy commonly causes nausea, vomiting, diarrhoea, and constipation, particularly during dose escalation
Of these patients, 1,284 met the inclusion criteria, 128 actively used a GLP-1RA, and 1,156 were not using a GLP-1RA
In patients with T2D in a phase 2 clinical trial, retatrutide (0.5 to 12 mg) significantly reduced body weight and HbA1c levels compared to placebo and 1.5 mg dulaglutide